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Abstract 
Background 
Use of veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) has 
become increasingly common as a means of providing hemodynamic support for 
patients in cardiogenic shock. Data regarding the efficacy of VA-ECMO are 
provided almost exclusively by single-center, retrospective analyses. These 
retrospective analyses vary significantly with regards to documentation of the 
underlying pathophysiologic process resulting in cardiogenic shock. 
Methods 
Relevant published studies were identified by using a comprehensive search of 
English-language MEDLINE from 1966 to November 2015. Relevant references 
found cited in these studies were also analyzed. These studies were analyzed 
with regard to the indications the authors used for initiation of ECMO, as well as 
the outcomes for each indication in each individual study. 
Results 
Analysis of multiple relevant studies regarding the indications for ECMO support 
demonstrated that there is a great deal of variability with regard to the use of 
different indications for initiation of ECMO support.  
Conclusions 
Data regarding the efficacy of VA-ECMO is derived largely from single-center, 
retrospective analyses.  In order to gain a better understanding of the efficacy of 
VA-ECMO in different patient populations, a more standardized format of 
documenting the indication for VA-ECMO should be used in centers that provide 
VA-ECMO. In general, all patients supported with VA-ECMO are in cardiogenic 
shock.  In our experience, the underlying processes leading to cardiogenic shock 
can be classified as: cardiac arrest, acute decompensated congestive heart 
failure, acute on chronic congestive heart failure, myocardial infarction, acute 
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pulmonary embolism, right ventricular failure not secondary to acute pulmonary 
embolism, and post-cardiotomy syndrome.   
Keywords 
VA ECMO, extracorporeal membrane oxygenation; heart failure; cardiogenic 
shock 
Abbreviations  
 
AVR -Aortic valve replacement  
 
Bi-VAD Bi-ventricular assist device  
 
CABG -Coronary artery bypass grafting  
 
CI – confidence intervals 
 
ECMO -Extra-corporeal membrane oxygenation  
 
HIT -Heparin-induced thrombocytopenia  
 
LV – left ventricle 
 
LVAD - Left ventricular assist device  
 
OR – odds ratio 
 
RV – right ventricle 
 
RVF – right ventricular failure 
 
VA -Veno-arterial.  
 
 
Introduction 
The first successful use of extra-corporeal membrane oxygenation (ECMO) for 
treatment of cardiogenic shock was described in 1973 (1). However, only 
recently has veno-arterial (VA) ECMO became a commonly used and, in some 
institutions, the preferred device for short term hemodynamic support in cardiac 
arrest or cardiogenic shock.  
Cardiogenic shock, defined as low cardiac output with poor tissue perfusion and 
end-organ damage, is a grave condition.   Spontaneous recovery is rarely 
possible.  A typical definition of cardiogenic shock usually includes multiple 
hemodynamic parameters with some variability. Such parameters may include 
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cardiac index less than 2.0 L/min/m2 with systolic blood pressure less than 100 
mmHg and pulmonary capillary wedge pressure ≥24 mmHg, and dependency on 
at least two inotropes or vasopressors with or without intra-aortic balloon pump 
support (2). With pharmacologic treatment, mortality is invariably high. In the 
SHOCK trial registry, patients with cardiogenic shock complicating an acute 
myocardial infarction (AMI) had in-hospital mortality of 60% (3).   
By the data from the Nationwide Inpatient Sample database, ECMO use in adults 
has increased significantly since 2007.  In 2002, the leading indication for 
initiation of VA-ECMO was post-cardiotomy syndrome (PCS) (56.9% of all 
cases).  By 2012, the proportion of  PCS as an indication for VA-ECMO 
decreased to 37.9% of cases, and cardiopulmonary failure as an indication 
increased from 3.9% (2002) to 11.1% (2012) (4). 
There are several reasons behind the increased use of VA-ECMO. Cardiogenic 
shock and cardiac arrest, regardless of the underlying pathological condition, are 
conditions most frequently managed by cardiologists. Unlike some other devices, 
ECMO can be placed at the bedside or in the catheterization laboratory.  Also, 
ECMO can be initiated not only by surgeons, but also interventional cardiologists. 
This increases access to this technology and the comfort level of using ECMO - 
not only by attending cardiologists but also cardiology fellows, who then begin 
practicing independently with an increased level of familiarity regarding the use of 
ECMO in critical situations.  
Another factor contributing to the wide acceptance of ECMO technology is 
progress in other areas of mechanical circulatory support, particularly left 
ventricular assist devices (LVADs). With the ability to maintain adequate 
hemodynamics in patients using an LVADs for several years, it became possible 
to use ECMO not only as a bridge to recovery, but also as a bridge to more 
permanent therapies such as a long-term LVAD or cardiac transplant. ECMO 
provides sufficient hemodynamic support and allows time to recover end-organ 
function and decide if the patient is salvageable (2).  Because ECMO can be a 
bridge to an LVAD, which can itself be a bridge to cardiac transplant, ECMO can 
serve as a bridge to bridge (4).   
Unlike other percutaneous short term devices, such as intra-aortic balloon 
counterpulsation devices, the TandemHeart (CardiacAssist, Inc., Pittsburgh, 
Pennsylvania), and Impella (Abiomed, Danvers, Massachusetts), ECMO can 
support the left ventricle (LV), right ventricle (RV), or both. It is also useful in 
incessant ventricular tachycardia, when isolated LV support is usually insufficient 
due to inadequate filling by the RV, which is equally affected by the arrhythmia. 
It can be predicted that the utilization of ECMO will only increase in years to 
come. We felt that it was useful to summarize the literature in terms of indications 
and outcomes of VA-ECMO in cardiogenic shock, and to discuss the 
classification of indications for ECMO that is currently in use. 
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Methods 
Relevant published studies were identified by using a comprehensive search of 
English-language PubMed from 1966 to November 2015 for the MeSH term 
‘‘Heart Arrest’’  or text words ‘‘heart arrest’’ or “cardiac arrest” MeSH term ‘‘shock, 
cardiogenic’’ or text word “cardiogenic shock”, MeSH term ‘‘extracorporeal 
circulation’’ or text word ‘‘extracorporeal circulation’’, or “extracorporeal 
membrane oxygenation”. In addition, the reference sections of the selected 
publications were manually screened for further relevant studies.   
Cardiogenic shock and cardiac arrest 
One of the distinctions that must be made is whether VA-ECMO is used for 
cardiogenic shock or cardiac arrest. In fact, cardiac arrest can be considered an 
extreme form of cardiogenic shock. When trying to analyze the outcomes of VA-
ECMO by indication, we found it difficult to separate cardiac arrest and 
cardiogenic shock. In acute myocardial infarction (AMI), cardiogenic shock 
develops due to a large portion of myocardium being affected by evolving 
ischemia and necrosis, which also leads to electric instability. If this results in 
ventricular fibrillation and cardiac arrest, and the ECMO is placed during 
resuscitation or immediately after restoration of spontaneous circulation, the case 
could either be classified as cardiogenic shock due to AMI, or as cardiac 
arrest/resuscitation. The physiology of AMI is different from cardiac arrest. On the 
other hand, cardiac arrest may result from other conditions, such as pulmonary 
embolism (PE), acute myocarditis, terminal chronic cardiomyopathy, right 
ventricular failure (RVF) due to a chronic pulmonary process, acute rejection 
after cardiac transplantation or PCS.  If the inciting pathophysiology of those 
underlying conditions persists post-arrest, we should classify the cases of cardiac 
arrest by their underlying etiology. However, if we agree that cardiac arrest, once 
it occurs, has the distinctly different physiology of a dying organism, then perhaps 
all cardiac arrest/resuscitation cases should be analyzed separately, regardless 
of the inciting pathologic process.  
In the past, authors of similar analyses have encountered same problem. Nichol 
et al. (5) performed a systematic review of case series in which ECMO was used 
for cardiogenic shock or cardiac arrest from 1966 to 2005.  By their data, there 
was a 50% survival rate when ECMO was used for cardiogenic shock and a 44% 
survival rate when it was used in cardiac arrest, but a statistically significant 
heterogeneity was found within each patient group. Other authors, comparing 
outcomes in cardiac arrest versus cardiogenic shock, also reported better 
survival in the latter. There is also increasing data on the efficacy of ECMO 
implanted during cardiopulmonary resuscitation (CPR).  
In the ESCLS registry, the definition of extracorporeal membrane oxygenation for 
adults in cardiac arrest (eCPR) is as follows: “extracorporeal life support (ECLS) 
used as part of initial resuscitation from cardiac arrest. Patients who are 
hemodynamically unstable and placed on ECLS without cardiac arrest are not 
considered E-CPR” (6). According to this definition, cases of ECMO facilitated 
cardiac arrest should be analyzed separately from cases of cardiogenic shock. 
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Per multi-institutional data from the Extracorporeal Life Support Organization 
(ELSO) registry, survival to hospital discharge in ECMO during CPR was 27% 
(6).   
For the purpose of this review, we attempted to focus on cardiogenic shock 
rather than cardiac arrest. In many cases, though, it was nearly impossible to 
separate cardiogenic shock from cardiac arrest because the reported series often 
include both. In the tables throughout this manuscript, we indicated in the 
comments how many cases out of each cohort had ECMO initiated during CPR. 
Ideally, we think that all such cases should be taken out of their original subsets 
and analyzed as ECMO during CPR, or eCPR. 
Like many therapies for critical conditions, ECMO is a difficult modality to study in 
a randomized controlled trial because the decision to utilize ECMO is commonly 
made instantaneously, not allowing time for research-specific procedures like 
randomization or informed consent. Because of this, information regarding the 
use of ECMO is obtained from registries. It is very important that registries 
documenting ECMO data follow some form of standard reporting that is clinically 
relevant.  
The primary international registry regarding ECMO is maintained by the 
Extracorporeal Life Support Organization http://www.elso.org (7), with the 
mission of providing support to institutions delivering ECLS through continuing 
education, guideline development, original research, publications, and 
maintenance of a comprehensive registry of patient data. Over 230 individual 
ECMO centers, including ours, enter data into this registry. Data are submitted to 
the registry by reporting centers using a standardized data collection form and 
include patient demographic information, diagnosis and procedure codes, pre-
ECMO support details, ECMO indication and support details, adverse events, 
and patient outcomes (8). 
The ELSO registry separates cardiac versus pulmonary runs, and VA versus 
veno-venous (VV) ECMO. Furthermore, within cardiac runs, it recognizes the 
following indications: cardiac arrest, cardiogenic shock, acute myocarditis, 
cardiomyopathy, congenital, and miscellaneous. Interestingly, not a single group 
of authors, analyzing their own data for publication, followed the same categories 
of indications for VA-ECMO in adults. 
Conditions within Cardiogenic Shock 
In this section, we summarized the distribution of indications for VA-ECMO 
reported by different authors. The classifications of indications are extremely 
heterogeneous, making the analysis difficult. Besides assigning their cases to 
different subsets, authors sometimes exclude large groups other than cardiac 
arrest/CPR. As an illustration, one retrospective study reporting the outcomes of 
their 26 patients with cardiogenic shock classified indications into AMI, 
decompensated chronic heart failure (HF), cardiac arrest, and   acute valvular 
pathology, but excluded post-cardiotomy shock (9). This is not an uncommon 
situation, but it skews the distribution of cases, making comparison between 
different institutions very difficult. One of the goals of this section is to 
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demonstrate the vast heterogeneity of reported indication and to present a 
evidence that there is a need for unified definitions and uniform classification of 
indications for ECMO in cardiogenic shock. 
As an example, Abrams et al. (10) used the following cardiac indications for 
ECMO initiation: AMI, fulminant myocarditis, septic cardiomyopathy, 
decompensated pulmonary hypertension with RVF, bridge to VAD or heart 
transplantation, right ventricular support during LVAD implantation in biventricular 
failure, PE, PCS, and primary graft failure post-heart transplantation.  Another 
group used different set of indications: AMI, acute HF, chronic HF, PCS, and PE. 
(11). When we analyzed our data, we used similar categories, with an addition of 
RVF due to chronic pulmonary disease. In general, it is difficult to identify even 
two studies where authors use similar classification for indications for VA-ECMO. 
The highest level of evidence for all indications is cohort studies, which make the 
importance of the registries even greater. Categories of indications for VA-ECMO 
support are summarized in Table 1.  
Burrell et al.(12) formed their cohort only from survivors, and therefore it was not 
comparable with other studies. 
The most controversial category is HF. It can be acute or acute-on-chronic, and 
can be reported and analyzed together or separately.  Differentiating 
cardiomyopathy from myocarditis is sometimes impossible, especially in the 
setting of an emergent situation. It seems reasonable to avoid using 
cardiomyopathy as an indication for ECMO, and to only differentiate acute or 
acute-on-chronic HF. All the cases of myocarditis will be then included in the 
acute HF group. Also, since congenital defects are so infrequent in the adult 
population, this group could be classified as “other/miscellaneous”.  Also, the 
indication “bridge to transplant or LVAD” should be distributed among other 
categories, because patients bridged due to hemodynamic instability in the 
setting of multiple different underlying conditions. 
The 2015 ECLS registry included the following categories: total (3406), cardiac 
arrest (283), acute myocarditis (51), cardiogenic shock (873), miscellaneous 
(1,785), congenital (163), cardiomyopathy (251). There are multiple problems 
with how the ECLS registry is categorized.  It is clear that these diagnostic 
categories do not correlate with what investigators use clinically.  Acute 
myocarditis and cardiomyopathy are similar indications.  All disease processes 
result in cardiogenic shock.  Lastly, if a miscellaneous group counts for half of the 
cases, it has to be divided into subtypes. 
Outcomes in typical indications for VA-ECMO 
Mixed Subsets  
Many authors reported their outcomes for mixed cohorts of patients, where some 
patients were receiving CPR at the time of ECMO insertion. In AMI, when ECMO 
was inserted in the absence of ongoing CPR, survival to discharge reached 55%.  
Survival to discharge when ECMO was placed during CPR was 12.5%. However,  
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Table 1. Classification/indications for VA-ECMO in Adults 
Author, 
Date 
Country 
N Car-diac 
arrest/ 
CPR 
Acute 
MI 
Acute 
myo-
carditis 
or AHF 
Post-
cardio-
tomy 
Primary 
graft 
failure 
after heart 
trans-
plant 
PE Acute on 
chronic HF 
Other 
indications 
Kolla(13) 
1996  
USA 
27 9 
(33.3%) 
 1  
(3.7%) 
7  
(25.9%) 
5  
(18.5%) 
  Bridge to 
transplant 5 
(18.5%) 
 Willms (14) 
1997  
USA 
 81 
  
68 
(84.0%) 
3  
(3.7%) 
  4 (4.9%) 2 (2.5%)  4 (4.9%) 
(dilated 
cardio-
myopathy)  
 
Bowen (15) 
2001, USA 
 
23 15  
(65%) 
8 
(34.8%) 
      
Hoefer (4) 
2006 
USA 
131   58(44.3%) 
(acute 
HF) 
62(47.3%)   11(8.4%)  
Combes (16) 
2008 
France 
81    16 
(19.8%) 
16 
(19.8%) 
16 
(19.8%) 
10 (12.3%)  18 (22.2%) 
(dilated 
cardio-
myopathy) 
Other 5 (6.2%) 
Liden(17) 
2009 
Sweden 
52    9 
(17.3%) 
2  
(3.8%) 
33 
(63.4%) 
   Other 8  
(15.4%) 
Bermudez (18) 
2011 
USA 
42  33 
(78.6%) 
    9 (21.4%)  
Barth (19) 
2012 
France 
  
242    32 
(13.2%) 
   112 (46.3%) Cir-
culatory collapse  
80 (33.1%) 
cardiogenic 
shock  
Guenther (20) 
2013 
Germany 
41  23 
(56.1%) 
13 
(31.7%) 
    Other 5 (12.2%) 
Chamogeorgakis 
(21) 
2013, USA 
61  32 
(52.5%) 
    29(47.5) 
all HF 
 
Loforte (22) 
2014, Italy 
228  27 
(11.8%) 
6  
(2.6%) 
118 
(51.8%) 
37 (16.2%)  40 
 (17.5%) 
 
Truby (23) 
2015 
USA 
179  46 
(25.7%) 
24 
(13.4%) 
acute HF  
70 
(39.1%) 
17(9.5%)   Other 22 (12.3%) 
Tarzia (24) 
2015 
Italy 
64  41 
(64%) 
6 (9.4%)    26 (56.3%)  Congenital 
defect 2 (3.1%) 
Carroll (11) 
2015 
USA 
 
123 
  
 35(28.5
%) 
13 
(10.6%) 
26 
(21.1%) 
 17 
(13.8%)  
15 (12.2%) 57 (46.3%) with 
cardiac 
arrest before 
ECMO 
17(13.8%) other  
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the predicted survival for this cohort was less than 10% (25), so utilization of 
ECMO demonstrated benefit. 
The largest series of ECMO recipients in a single institution was reported from 
the National Taiwan University Hospital, where ECMO was utilized for 607 
patients (26). Unfortunately, there were no specific indications for ECMO support 
reported in this paper. The overall survival to discharge was 30.1%. Independent 
predictors of mortality included age, stroke, need for dialysis during ECMO, pre-
ECMO infection, hypoglycemia, and alkalosis (26).  Per other authors, 
independent predictors of intensive care unit death were the following: device 
insertion during CPR (OR = 20.68), 24 hour urine output < 500 mL (OR = 6.52), 
prothrombin activity < 50% (OR = 3.93), and female sex (OR = 3.89); myocarditis 
was associated with better outcomes (OR = .13) (16). Other factors associated 
with poor prognosis were older age, longer support time, decreased cardiac 
function at the baseline (27), higher lactate concentration, peripheral vascular 
disease, pre-operative chronic obstructive lung disease, ejection fraction, and 
renal dysfunction (11, 28). 
Survival in Acute MI 
Outcomes in AMI were often reported with inclusion of patients suffering cardiac 
arrest in the setting of acute MI. Because, as previously mentioned, the 
outcomes are worse in the setting of cardiac arrest, the resulting numbers are 
difficult to interpret. In the tables below, all studies are retrospective and single 
center, unless indicated otherwise. 
Almost all cohorts included patients that suffered cardiac arrest, which should 
increase mortality. The outcomes are very heterogeneous, with survival to 
hospital discharge ranging from 19% (29) to 87.5% (30). This last result was from 
very small series with only eight observations. Part of the heterogeneity may be 
due to the fact that there is a mixture of cardiogenic shock and cardiac arrest in 
the setting of AMI (Table 2). 
ECMO was able to save patients even with potentially fatal complications of 
acute MI such as free wall rupture, ventricular septal defect, and mitral 
regurgitation due to papillary muscle rupture. Out of nine patients with such 
complications, four were discharged, three of them in good neurological condition 
(31).  
In AMI, longer CPR time and support time, increased cardiac enzymes, lower 
ejection fraction, lower albumin, and major complications were risk factors of 
mortality (32). 
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Table 2. Outcomes of VA-ECMO in Acute Myocardial Infarction 
Author, date N Survival 
On ECMO, 
% 
Sirvival to 
discharge, 
% 
Survival 30 days,  
% 
Time on 
ECMO 
Comments 
Shawl, 1989 
(30) 
 8 87.5 87.5 87.5  2 in cardiac arrest 
Matsuwaka, 
1996 (29) 
16 87.5 19 37.5  AMI (n = 7), or post-
infarction  LV  free 
wall rupture (n = 9) 
Sheu, 2010 (33)   46   60.9  30 day survival 
without ECMO with 
similar hemodynamic 
28% 
 Aiba, 2001 (34)  26 35 19.2     
Chen, 2006 (25) 36 69.4 33.3    108.5±  
 77.5 hrs 
eCPR in all 
Brunet, 2008 
(35) 
8  25 25   4 e CPR 
  
Bermudez, 
2011 
(18) 
 33 
 
  64 
 
 
69 hours (3–
352) 
 
Survival 48% at 1 and 
2 years 
 
Chung, 2011 
(32) 
20 70 50  3.8±4.0 days CPR in 14 cases 
Sakamoto, 
2012 (36) 
98 55.1 
 
       
32.7 
  
 Mean 68.9  ± 
62.7 hours  
  64 eCPR during   
Negi, 2015 (37) 15 50 47 47 Mean 45 
hours 
5 after cardiac arrest 
Esper, 2015 
(38)  
 
18  67  3.2 +/- 2.5 
days 
 
Carroll*, 2015 
(11)  
 
 35  50   28    14 eCPR   
* The data are presented as a graph only, we made our best estimate 
Survival in Heart Failure 
There are several indications for ECMO within acute HF, and they are also 
reported inconsistently. Acute myocarditis (Table 3), acute HF, acute on chronic 
HF (Table 4), cardiomyopathy – all these terms are used in the ECMO literature, 
making the outcome comparison challenging. Septic cardiomyopathy is 
sometimes reported separately (Table 5). Several authors commented on higher 
survival rates in fulminant myocarditis than in other indications for ECMO (39). In 
the analysis from the  ECLS  registry, acute myocarditis was a favorable factor 
for survival ( OR : 0.18; 95% confidence interval  CI : 0.05 to 0.69) (6). It is 
important to remember that other categories such as AMI are not recognized as 
diagnostic entities by the registry. 
Few authors reported the outcomes of acute on chronic HF as a separate 
category. 
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Table 3. Outcomes of VA-ECMO in Fulminant Myocarditis 
Author, date N Survival 
On ECMO, 
% 
Sirvival to 
discharge, 
% 
Survival 
30 days, 
% 
Time on ECMO Comments 
Kawahito, 
1998 (40) 
6 83.3 83.3   200 ± 52 hours  
Range 32-399 
 
Kato, 1999 
(41) 
9 100 77.8 88.9 6.4 ± 2.2 days  
 Asaumi, 2005 
(42) 
 14 71  71  71 median 130 (42–171) 
h (max 12 days) 
 No further death in 3-5 
years 
 Pages, 2009 
(43) 
 6 83.3 83.3 83.3 13 ±4 days Outcomes are similar to 
biventricular assist device 
Gariboldi, 
2010 (44) 
10  70   Median 12 days  
Carroll, 2015 
(11) 
 
 13 80   70     Numbers are presented on 
the graph, we took our best 
estimate  
Hsu, 2011 (45) 75  64  171.5 ± 121 hours 
 
  
23 5 eCPR 
Mirabel, 2011 
(46) 
35  68.6   5 eCPR 
Wu, 2012 (47) 16  87.5    
Ishida, 2013 
(48) 
20  60    
Diddle, 2015 
(8) 
  61   21% inserted during CPR 
 
Data from ELSO  
 
Table 4. Outcomes of VA-ECMO in Acute on Chronic HF 
 
 
Table 5. Outcomes of VA-ECMO in septic cardiomyopathy 
Author, date N Survival 
On 
ECMO,% 
Sirvival to 
discharge, 
% 
Survival 
30 days, 
% 
Time on 
ECMO 
Comments 
Brechot, 2013 
(49) 
 14  86  71      All 10 survivors alive after a 
median of 13 (3–43) months   
 Huang., 2013 
(50)  
 52    15     21(40%)  eCPR 
Author, date N Survival 
on 
ECMO,% 
Sirvival to 
discharge,% 
Survival 
30 days, 
% 
Time on 
ECMO 
Comments 
Bermudez 
2011 
(18) 
9     
 
  
 
  
  
56  60 
hours 
(1–274) 
11% at 1 and 2 years  
Carroll, 2015 
(11) 
 15  47   40     Numbers are presented on 
the graph, we took our best 
estimate  
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When patients with cardiomyopathy were bridged with ECMO to recovery, LVAD 
or transplant, overall survival to discharge was 49%.  26% of these patients were 
transitioned to implantable VADs, 18% recovered sufficient native cardiac 
function, and 11% were bridged to transplantation. CPR at the time of 
implantation was an independent predictor of in-hospital mortality (odds ratio: 
5.79; p = 0.022) (18). 
Survival in Right Ventricular Failure due to Chronic Lung Disease 
VA-ECMO is emerging as a cardiopulmonary support modality for RV failure due 
to chronic pulmonary disease, especially if there is a potentially reversible cause 
of exacerbation of a chronic process (such as acute pneumonia) or if ECMO 
serves as a bridge to transplant.  Still, VV ECMO is a more common modality in 
this settings, and the outcomes are often reported for VV and VA-ECMO 
combined (51-54). In a single institution series, VA-ECMO was used in 6 patients 
with primary arterial pulmonary hypertension or pulmonary hypertension due to a 
congenital defect (in two cases, the artery was not, in fact, cannulated, but large 
atrial septal defects created the access to systemic arterial circulation). Both 
bridge to transplant patients were successfully weaned off ECMO and 
discharged home after lung transplant. Out of 4 patients who were placed on 
ECMO because of acute destabilization, 3 were in cardiac arrest. Three out of 4 
survived to weaning off ECMO, and two survived to discharge (54).  In the 
Hoopes et al.(53) paper, the indications for VA-ECMO included pulmonary 
fibrosis, cystic fibrosis, and pulmonary hypertension. Despite currently limited 
literature, this area will likely continue to expand, and it is reasonable to analyze 
it as a separate category (Table 6). 
Table 6. Outcomes of VA-ECMO in right ventricular failure due to chronic lung 
disease 
 
Author, date N Survival 
On 
ECMO,% 
Sirvival to 
discharge,% 
Survival 
30 days, 
% 
Time 
on 
ECMO 
Comments 
Ollson, 2010 (55) 5 60 60   All bridge to 
lung 
transplant 
Hoopes, 2013 
(53) 
19   94.7 94.7     2 
institutions 
 
Rozenshweig, 
2014 (54)  
 6   83.3  66.7       
 
Survival in Pulmonary embolism 
Massive PE with acute RV failure with circulatory collapse is another indication 
for VA-ECMO. Similar to other indications for VA-ECMO support, the information 
is coming from retrospective single center series (Table 7) 
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Table 7. Outcomes of VA-ECMO in pulmonary embolism 
 Author, date N Survival 
On 
ECMO,% 
Sirvival to 
discharge,% 
Survival 
30 days, 
% 
Time on 
ECMO 
Comments 
 Kawahito, 2000 (56)    57  57 57  18-168 
hours   
Mean 
67.8±67.1 
 
Maggio, 2007 (57)  
21 
   62     mean 113 ± 
97 hours or 
4.7 days 
  Eight were 
in active 
cardiac 
arrest.  
 Munakata, 2012 (58)   
10 
     70  Mean 48 ± 
44 hours 
Median 23 
hours 
 9 in cardiac 
arrest 
Akkanti, 2015 (59)  4 100 100    
 
Survival in Post heart transplant for primary graft failure 
The outcomes of VA-ECMO for post-heart transplant graft failure are shown in 
Table 8. 
Table 8. Outcomes of VA-ECMO in Primary Graft Failure after Heart Transplantation 
Author, date N Survival 
On 
ECMO,% 
Sirvival to 
discharge, 
% 
Time on ECMO Comments 
Ko, 2002 (60)  9   77.7  44.4       
Taghavi, 2004 
(61) 
13  77  54 72.4 ±61.6 RVF 
Comparing with RVAD, ECMO is better. 
Weaning (77% versus 13%; p< 0.001  ) 
Leprince, 2005 
(62) 
14    78.6  50 5 ±  2.5 days 3 with pulmonary HTN, 3 from marginal 
donors  
Chou, 2006 (63) 19   84.2  52.6 157 +/- 129 hours.   Compared with data from VAD-supported 
PCAGF, ECMO had a better weaning and 
graft survival rates (p < 0.05) 
Arpesella, 2008 
(64) 
 11     9.1 +/- 6.9 days 
(range, 1-18 days) 
 
D'Alessandro, 
2010 
(65) 
54 67 50  Patients treated with ECMO have the same 
1-year conditional survival as patients not 
having suffered EGF: 94% at 3 years 
 Marasco, 2010 
(66) 
39 87 74.3    Comparison of survival in the 39 ECMO 
patients to the non-PGF patients (n = 185) 
showed a significantly worse survival in 
the ECMO group (p = 0.007). When those 
patients who died in the first 30 days were 
excluded, there was no difference in overall 
survival between groups (p = 0.73). 
 
Survival in Postcardiotomy cardiogenic shock    
Post-cardiotomy cardiogenic shock is a rare but often fatal complication of 
cardiac surgery.  In approximately 1% of all cases, patients cannot be weaned off 
cardiopulmonary bypass, and VA-ECMO is the only viable option for 
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hemodynamic support (39) (Table 9).  Predictors of mortality included age, 
diabetes, and longer time on cardiopulmonary bypass (67). 
Table 9. Outcomes of VA-ECMO in Postcardiotomy Syndrome 
 
Author, date N Survival 
On ECMO, 
% 
Sirvival  
to dis-
charge, 
% 
Survival 30 
days, % 
Time on ECMO Comments 
Magovern, 1994 
(68) 
21 
 
 57.1 
  
   
Kawahito, 1994 
(69) 
 13  77      1 to 66 hr 
(mean 27.4 +/- 
26.7), 
 
 Wang, 1996 
(70) 
 18  52.6  33.3      
Muehrcke, 1996 
(71) 
23  56.5 30.4  58.4 +/- 35.1 
hours (range, 
0.5 to 144 hours 
Including 4 post 
heart transplant 
Kitamura, 1999 
(72) 
64 50 26.7   76.2% and 57.1% 
with biventricular 
bypass, 87.5% 
and 37.5% with 
isolated left 
ventricular 
bypass, and 
60.0% and 40.0% 
with pulsatile left 
ventricular 
assistance 
Sasaki(73) 9 66.7 55.5  84.3 +/- 6.3 hrs  
Hata, 2000 (74)  30  56.7  43.3     
Hayashi, 2000  
(75) 
9 100 66.7    
Ko, 2002 (60) 76 60.5 26.3  99±32 hours. Including 9 post 
heart transplant, 
presented 
separately in the 
next table. 
Doll, 2004 (76) 219 60 24 24 2.8 +/- 2.2 days 74% of the 
discharged alive 
in 5 years 
Bakhtiary, 2008 
(77) 
45 55.5 29 47 6.4 ± 4.5 days 1 post heart 
transplant 
In 3 years, 22% of 
the initial cohort 
was alive 
Liden, 2009 (17) 33  45  5.59±4.9days  
Elsharkawy, 2010 
(67) 
233  36    
 Hsu, 2010  (78) 51 53   33 51  29% alive in 1 
year 
Carroll, 2015  
(11) 
 26  50 24     Numbers are 
presented on the 
grapf, we took 
our best estimate  
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 ECMO to prevent acute right ventricular failure after LVAD implantation 
One of the newest indications for VA-ECMO is RVF after LVAD implantation, 
when the RV is potentially recoverable but needs time to adjust to new 
hemodynamic conditions (10). Although the numbers are likely small, this 
indication is so different from the others, that we think it should be collected and 
analyzed separately. 
Outcomes by Indications 
As previously mentioned, patients supported with ECMO in the setting of both 
fulminant myocarditis and PE have good rates of survival. In one study, patients 
with PE (odds ratio 8.0, 95% confidence interval 2.00 to 31.99; p =0.01) and 
acute cardiomyopathy (odds ratio 7.5, 95% confidence interval 1.69 to 33.27; p= 
0.01) had a higher rate of survival than that of acute myocardial infarction, 
chronic cardiomyopathy, and miscellaneous etiologies compared to post-
cardiotomy cardiogenic shock as a referent (11). However, in another cohort, 
survival in cardiomyopathy was worse than in AMI (18). 
Proposed Classification of Indications for ECMO in Cardiogenic Shock 
Data regarding the efficacy of VA-ECMO is derived largely from single-center, 
retrospective analyses.  In order to gain a better understanding of the efficacy of 
VA-ECMO in different patient populations, a more standardized format of 
documenting the indication for VA-ECMO should be used in centers that provide 
VA-ECMO. We believe that developing a more uniform and clinically relevant 
way of categorizing the indications for initiation of VA-ECMO support in patients 
with cardiogenic shock is essential to gaining a better understanding of which 
patient groups may or may not benefit from VA-ECMO support. 
In general, all patients supported with VA-ECMO are in cardiogenic shock.  
Therefore, the underlying pathophysiologic process leading to cardiogenic shock 
should be identified and documented as the indication for VA-ECMO support in 
addition to cardiogenic shock.  It has been our experience that the underlying 
processes leading to cardiogenic shock can be classified in the following 
categories: cardiac arrest, acute decompensated congestive heart failure, acute 
on chronic congestive heart failure, myocardial infarction, acute PE, RVF not 
secondary to acute PE, and PCS.  
The cardiac arrest category is the most difficult to classify because patients who 
suffer cardiac arrest typically have another underlying process, such as AMI or 
acute PE, and the potential for meaningful recovery may depend on reversibility 
of the underlying process. However, patients who suffer cardiac arrest have a 
poorer prognosis than patients who are in cardiogenic shock due to a process 
such as AMI or acute PE in the absence of cardiac arrest. Therefore, we propose  
that patients should be classified in a group of cardiac arrest, regardless of the 
underlying cause of cardiac arrest.  Both cardiac arrest and any other underlying 
process should be documented. In addition, if a patient is initiated on VA-ECMO 
while actively undergoing CPR, this should be documented as eCPR.  This will 
help analyze the efficacy of initiating VA-ECMO support during CPR, which could 
potentially change future clinical practice.  
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The classification of acute decompensated heart failure should be used for 
patients with no history of heart failure who are in cardiogenic shock due to new-
onset cardiomyopathy. This group would include patients such as those in 
cardiogenic shock due to fulminant myocarditis, stress-induced cardiomyopathy, 
viral cardiomyopathy, peripartum cardiomyopathy, etc. It is necessary to 
differentiate this group from patients suffering acute on chronic decompensated 
heart failure because the natural course of the disease process is very different 
due to higher potential to regain cardiac function. Patients with a history of 
chronic cardiomyopathy may be more likely to require more long-term 
mechanical support, such as a LVAD, or heart transplant, and would potentially 
demonstrate decreased benefit from VA-ECMO when compared to patients with 
no history of cardiomyopathy.  
Patients in cardiogenic shock due to AMI should be classified into one category 
due to the distinct nature of this condition.  Cardiac recovery in the setting of AMI 
is variable, and typically depends on the ability to provide timely 
revascularization.  In addition, patients may suffer the inherent complications of 
AMI such as an unstable arrhythmia, acute mitral regurgitation, mechanical 
complications such as free wall rupture, etc. Not only should AMI be 
documented, but mechanical complications contributing to cardiogenic shock 
should be documented as well.   
Patients with no history of left or right ventricular dysfunction who are in 
cardiogenic shock due to right heart failure in the setting of an acute PE should 
be separated from patients with chronic right ventricular dysfunction. Patients 
with acute PE and no underlying right or left ventricular dysfunction have a fairly 
reversible cause of cardiogenic shock, and would likely demonstrate increased 
benefit from VA-ECMO when compared to patients with chronic right ventricular 
dysfunction resulting from pulmonary arterial hypertension or pulmonary fibrosis, 
for example. Given the difficulty in treating or reversing these underlying 
conditions, patients with chronic, isolated RVF would likely demonstrate 
decreased benefit from VA-ECMO than patients with RVF due to acute PE with 
no underlying cardiomyopathy.  
Patients who are supported with VA-ECMO in the setting of recent cardiac 
surgery should be classified into a separate group such as a PCS group. This 
group would include patients with recent coronary artery bypass grafting, valvular 
surgery, or any other cardiac surgery. Often, these patients cannot be weaned 
from cardiopulmonary bypass in the operating room, or may develop cardiogenic 
shock in the post-operative course due to complications or the natural sequela of 
critical illness. This group has demonstrated poor survival when supported with 
VA-ECMO in the setting of cardiogenic shock.  
Conclusion 
The use of VA-ECMO to provide MCS in the setting of cardiogenic shock has 
become increasingly more common over the past several years. The decision to 
initiation VA-ECMO support typically occurs in an emergency setting, making it 
difficult to evaluate the efficacy of VA-ECMO support in a prospective, 
randomized controlled trial. The vast majority of objective evidence regarding the 
 
 
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.08 Page 16 of 22 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
efficacy of VA-ECMO support in the setting of cardiogenic shock comes from 
retrospective analyses in single-centers. In order to obtain data to help guide 
clinical practice regarding the decision to utilize VA-ECMO as a means of 
providing MCS, there should be a more uniform system of documentation of the 
underlying etiology of cardiogenic shock across centers that utilize VA-ECMO.  
This review demonstrates the extensive variability in the documentation of the 
indications for MCS with VA-ECMO in the setting of cardiogenic shock across 
different centers utilizing VA-ECMO. We propose that the etiologies should 
include cardiac arrest, acute decompensated congestive heart failure, acute on 
chronic congestive heart failure, AMI, acute PE, RVF not secondary to acute 
pulmonary embolism, and PCS. We believe that these disease processes include 
the majority of disease processes causing cardiogenic shock and need for MCS, 
and that they differ with regard to pathophysiology, prognosis, and management. 
If centers providing support with VA-ECMO document the etiology of cardiogenic 
shock in a uniform manner, it will be possible to obtain more accurate and 
clinically relevant data regarding the efficacy of VA-ECMO in these patient 
populations, which may assist in guiding management strategies in patients with 
cardiogenic shock.  
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